Perfusion & Concentrated Perfusion

PROCESS COMPARISON

Which Process Option is Right for Me?
A Comparison of Fed-Batch, Perfusion and Concentrated Perfusion

When determining how to develop a bioprocess for your drug candidate, there are many key decisions about how to proceed including choosing a cell line, whether to outsource or keep in-house, and what type of bioprocess is most economic.

The old fed-batch and perfusion processes are well known but both have limitations. If you wish to move to a modern production platform, which one is best?

If you already have a facility this will impact significantly your cost base and therefore your choice, but today, most people wish to evaluate all opportunities that could reduce the cost of development and the cost of manufacture. Here is an overview about the four main process options commonly available. (note that batch processing is ignored here)

Typical questions may include:
Should I use fed-batch rather than perfusion? Which is lower cost? Which involves less risk? What about the concentrated perfusion processes? How do I know which process option is right for me?

…here are some ideas and answers:

Perfusion, Concentrated Perfusion and Fed-Batch

Use Perfusion if you want to:

  • keep a low cell density of 30m or less for reasons of cell or product stability, for example because the concentration of a required toxic molecule will be too difficult to control.
  • replicate a process that is moving from older style perfusion technology, such as a spin filter or cell settler, and just wish to benefit from the ATF™ System’s improved reliability and gain a filtered product stream - but wish to maintain a similar cell density as previously.

Use Concentrated Perfusion (Perfusion with the ATF System) if you want to:

  • reduce the size of bioreactor required to produce to same amount of product as in fed-batch or perfusion
  • reduce the time taken to produce X kilograms of your molecule
  • reduce USP development times
  • standardize process control and improve the reliability of reactor performance
  • reduce the complexity of media development and use only a single medium feed
  • remove contaminants and by-products from the reactor and improve product quality
  • maintain a constant environment for cell growth and/or product expression
  • utilize an existing DSP train that is suited to receive one or two vessel volumes per day of clarified material at 1-2g/L concentration.
  • take advantage of moving towards continuous processing in downstream activities.

Use Fed-Batch if you want to:

  • utilize effectively your existing 10,000L or 20,000L reactor

Comparison Table

  Perfusion Concentrated Perfusion Fed-Batch
Feed medium Complete medium medium Complete medium (multiple) Feed concentrate medium
Environment Constant Constant Changing
Osmolarity change Constant Constant Increasing
Waste / toxic molecules Removed Removed Accumulated
Product residence time Low Low High
Stability of environment for product High High Low
Typical Process Duration 1-2 months 1-2 months 1-3 weeks
Typical cell concentration 10-30m 60-120m 10-30m
Typical cell viability during production 75-95% 75-95% 30-95%
Typical cell viability at harvest 75-95% 75-95% 30-70%
Compatible with disposable reactors? Yes Yes Yes
Compatible with Cell Banking™ with the ATF System? Yes Yes Yes
Compatible with ATF-manufacturing™? Yes Yes Yes
Seed train (litres) 8 Stages:
1ml (vial), 5ml, 25ml, 125ml, 600ml, 3L, 15L, 75L
8 Stages:
1ml (vial), 5ml, 25ml, 125ml, 600ml, 3L, 15L, 75L
10 Stages:
1ml (vial), 5ml, 25ml, 125ml, 600ml, 3L, 15L, 75L, 400L, 2000L
Seed train with ATF-manufacturing™ Platform (litres) 2 Stages:
100ml (bag), 10L
2 Stages:
100ml (bag), 10L
3 Stages:
100ml (bag), 10L, 500L
Typical manufacturing vessel size 500L 500L 10,000L
Media cost per litre Moderate Moderate High
Media volume required High (1-2vvd) High (1-2vvd) Low (1vv)
Harvest Daily / constant Daily / constant 1 per batch
Process control requirements High High Moderate
Operation skill required High High Moderate
Alkali addition Low Low Moderate
§Compatible with continuous DSP Yes Yes No
Output from 1000L reactor, per day 0.2kg 0.8kg n-a
Output from 1000L reactor, per run (CHO cell data) 6kg
(20m cells per ml)
(30 days)
24kg
(80m cells per ml)
(30 days)
1.2kg
(peak 20m cells per ml)
(14 days)
Time to produce 10Kg of product 1-2 Batches
~7 weeks
1 Batch
~2 weeks
8-9 Batches
~22 weeks
Yearly output from 1000L reactor 60kg
(10 runs)
240kg
(10 runs)
24kg
(20 runs)
Reactor size required to produce ~250Kg oer year 4x 1,000L 1x 1,000L 1x 10,000L

§ Model data taken from CMC ICOS webinar 2009 presented through Bioprocess International (available in the download tab) and from one of Refine Technology’s pharmaceutical clients

Process Comparison Table by Minnesota University

  Perfusion * Concentrated Perfusion * Fed-Batch *
Scale 400L 400L 15,000L
Length 50-180 days 30-60 days 15-20 days
Osmolarity change 6-100 x 106 60-120 x 106 6-10 x 106
Cell Line Stability - - +
Product Concentration +/- + +
Productivity + + +
Product Residence Time + + -
Process Simplicity - - -
Process Control - - -
Contamination Risk - - +
Operation Costs + + +/-

* Data from CD-ROM Cell Retention and Perfusion, by Chun Zhang, Cell and Tissue Reactor Engineering, © 2003 University of Minnesota
** Data estimated on similar basis by Refine Technology

RELATED LINKS

RELEVANT DOWNLOADS

EVENTS

  • Please join us at the following conferences & exhibitions:

Feb
27

February 27 - February 29, 2012
4th Annual Disposable Solutions for Biomanufacturing
Brussels

Apr
02

April 02 - April 04, 2012
ISBioTech 2nd Annual Meeting
Virginia

Apr
11

April 11 - April 13, 2012
World Vaccine Congress 2012
Washington

Apr
18

April 18 - April 19, 2012
BioProcess International Europe 2012
Prague

REFINE NEWS